STIMATE — Class I drug recall D-1506-2020
Terminated recall by Ferring Pharmaceuticals Inc, reported 2020-08-26, distributed nationwide. Superpotent Drug
| Recall number | D-1506-2020 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Ferring Pharmaceuticals Inc, Parsippany, NJ, United States |
| Recall initiated | 2020-07-21 |
| Classified | 2020-08-17 |
| Reported by FDA | 2020-08-26 |
| Terminated | 2023-10-13 |
| Distributed | Nationwide (US) |
| Quantity | 29,371 nasal |
| Reason classes | potency |
| NDC | 00053-6871-00 |
| Lot numbers | 2020, 2021, 2022, N14134C, N15378G, N17445N, P11326AA, P11326C, P13209L, P13212H, P13755A, P13756P, R11845A, R13271A, R13648A, R14101A, R14667A, R15953C |
Product
STIMATE (desmopressin acetate) Nasal Spray1.5 mg/mL, 2.5 mL glass vial with spray cap, Rx only, Manufactured for: CSL Behring LLC, King of Prussia, PA 19406-0901; By: Ferring GmbH, Kiel, Germany, NDC 0053-6871-00
Reason for recall
Superpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1506-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.